Nexavar (Sorafenib)

Sorafenib, the active ingredient in Nexavar, is a multi-kinase inhibitor presented as a tablet for oral use. It treats certain advanced cancers such as renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid carcinoma, and advanced gastrointestinal stromal tumor in adult patients.

GNH USA supplies Nexavar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Sorafenib is used to target malignant tumors that rely on kinase‑driven proliferation and angiogenesis.

Renal cell carcinoma: prolongs progression‑free survival in advanced disease. Hepatocellular carcinoma: improves overall survival in patients with unresectable disease. Differentiated thyroid carcinoma: delays disease progression in radioactive‑iodine‑refractory cases. Advanced gastrointestinal stromal tumor: provides disease control after failure of prior tyrosine‑kinase inhibitors.

Sorafenib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea - Hypertension - Fatigue - Rash

Serious or Rare Side Effects: - Severe bleeding - Hepatic failure - Cardiac ischemia

When prescribing Sorafenib, clinicians should consider several safety measures.

Monitor blood pressure: check regularly and manage hypertension. Assess liver function: perform baseline and periodic tests. Evaluate cardiac status: monitor for ischemic events. Review wound healing: delay elective surgery if possible due to anti‑angiogenic effect. Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Sorafenib can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): reduce Sorafenib exposure. - Antiplatelet agents (e.g., aspirin): increase bleeding risk. - QT‑prolonging drugs (e.g., sotalol): may exacerbate cardiac risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): increase Sorafenib levels. - H2 blockers or PPIs: may affect absorption. - Statins metabolized by CYP3A4 (e.g., simvastatin): consider dose adjustment.